Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.69 |
| ▸ | THPO | P40225 | 2/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.69 |
| ▸ | GMNN | O75496 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.69 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.69 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.66 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113384 | 0.85 | ALDH1A1 (0.77) | HDAC6ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL4789384 | 0.83 | CA12 (0.75) | HDAC6ALDH1A1SMN1; SMN2HIF1ALMNA | |
| Chlorambucil SCHEMBL5318105 | 0.82 | SMN1; SMN2 (1.00) | HDAC6ALDH1A1SMN1; SMN2HIF1ALMNA | |
| Chlorambucil SCHEMBL4308 | 0.82 | SMN1; SMN2 (1.00) | HDAC6ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL7470724 | 0.82 | ALDH1A1 (0.77) | HDAC6ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL11516322 | 0.82 | ALDH1A1 (0.77) | HDAC6ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL7907639 | 0.82 | HDAC6 (0.89) | HDAC6ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL7914324 | 0.82 | HDAC6 (0.89) | HDAC6ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL4616980 | 0.81 | ALDH1A1 (0.75) | HDAC6ALDH1A1SMN1; SMN2HIF1ALMNA | |
| Chlorambucil SCHEMBL28942852 | 0.81 | SMN1; SMN2 (0.91) | HDAC6ALDH1A1SMN1; SMN2HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552176-B2 | Glycosylated chlorambucil analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552176-B2 | Glycosylated chlorambucil analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552176-B2 | Glycosylated chlorambucil analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120094946-A1 | GLYCOSYLATED CHLORAMBUCIL ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094946-A1 | GLYCOSYLATED CHLORAMBUCIL ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-6709679-B2 | CONSISTING OF NATIVE OR THIOLATED TRANSFERRIN OR ALBUMIN OR OF POLYETHYLENE GLYCOL WITH ATLEAST ONE MERCAPTAN, HYDROXY OR AMINE GROUP AND CYTOSTATIC COMPOUNDS DERIVED THROUGH MALEINIMIDE OR HYDROXYSUCCINIMIDE ESTER COMPOUNDS | KRATZ FELIX (DE) | 2004-03-23 | — | — | US | disclosed |
| US-20020019343-A1 | Antineoplastic conjugates of transferrin, albumin and polyethylene glycol | KRATZ FELIX (DE) | 2002-02-14 | — | — | US | disclosed |
| US-6310039-B1 | TUMOR-INHIBITING CONJUGATES OF PROTEINS AND POLYMERS CONSISTING OF A SUITABLE CARRIER SYSTEM AND CYTOSTATIC COMPOUNDS | KRATZ FELIX (DE) | 2001-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019343-A1 | Antineoplastic conjugates of transferrin, albumin and polyethylene glycol | TFRC, ALB, FOLR1 | HDAC6 616/4885ALDH1A1 2933/4885SMN1; SMN2 3377/4885 |
| US-20120094946-A1 | GLYCOSYLATED CHLORAMBUCIL ANALOGS AND USES THEREOF | CD22, UGGT1, UGCG | HDAC6 289/4885ALDH1A1 296/4885SMN1; SMN2 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.